KURA insider trading
NasdaqGS HealthcareKura Oncology, Inc.: insider trade history from SEC Form 4 filings.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Company website: kuraoncology.com
KURA insider activity at a glance
FilingIQ tracks 215 insider transactions for KURA in filings since Dec 17, 2015. The most recent transaction is dated Sep 29, 2026.
Across the full history, 15 open-market purchases
and 111 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KURA insider trades is 54.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KURA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for KURA?
- FilingIQ tracks 215 Form 4 insider transactions for KURA (Kura Oncology, Inc.), covering filings from Dec 17, 2015 onwards. 15 of those are dated within the last 90 days.
- Are KURA insiders net buyers or net sellers?
- Across the full Form 4 history for KURA, 15 transactions (7%) were open-market purchases and 111 (52%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KURA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is KURA in?
- Kura Oncology, Inc. (KURA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $718.76M.
Methodology & sources
Every KURA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.